Roth Capital Positive on Galena (GALE) Following Quick Enrollment of GALE-401 Phase 2
Tweet Send to a Friend
Roth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following an update on Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
